Compare Nutanix Inc (NTNX) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Nutanix Inc trades at $74.63 (market cap $19.78B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 3× Nutanix Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| NTNX | TAK | |
|---|---|---|
Market Cap | $19.78B | $58.74B |
Volume | 1,717,619 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $73.42 | $19.05 |
52-Week Low | $34.41 | $13.23 |
Typical Hold Time | 17 Days | 1 Days |
Enterprise Value | $18.94B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $73.08, down 0.46% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $76.11. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.60 surpassing the $0.49 expectation. Revenue growth is robust, projected to rise from $2.54 billion in 2025 to $2.9 billion in 2026, while net income margin expanded significantly to 52.81%.
The outlook remains positive driven by strong execution, external storage partnerships, and AI growth initiatives, though high valuation multiples like EV/EBITDA of 46.22 and negative ROE of -395.76% pose risks. Investor sentiment is buoyed by recent Gartner recognitions and earnings beats, but supply chain pressures and competitive threats require monitoring.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
